- Biological treatments for severe asthma
-
Hyun Jung Jin
-
Yeungnam Univ J Med. 2020;37(4):262-268. Published online September 11, 2020
-
DOI: https://doi.org/10.12701/yujm.2020.00647
-
-
7,287
View
-
185
Download
-
12
Crossref
-
Abstract
PDF
- Severe asthma patients comprise about 3% to 13% of all asthma patients, but they have higher hospital utilization rates and higher medical costs than those of nonsevere asthma patients. Treatment methods for severe asthma patients are still lacking; however, the recent development of biologics is expected to have a positive effect. The biological therapies developed so far are mainly aimed at treating asthma patients with type 2 inflammation. These biologics have been found to reduce symptoms of asthma, improve lung function, reduce the use of oral corticosteroids, and improve quality of life of patients. This article reviews the mechanism of action and indications for approved biologics and discusses what should be considered when choosing biologics.
-
Citations
Citations to this article as recorded by
- Current and Novel Biologic Therapies for Patients with Asthma and Nasal Polyps
Hanna K. Mandl, Jessa E. Miller, Daniel M. Beswick Otolaryngologic Clinics of North America.2024; 57(2): 225. CrossRef - Moderate-High Blood Eosinophilia Is Associated with Increased Hospitalization and Other Asthma Comorbidities
Sara Naharro-González, Clara Lorente-Sorolla, José Manuel Rodrigo-Muñoz, Marcela Valverde-Monge, Erwin Javier Pinillos-Robles, Diana Betancor, Mar Fernández-Nieto, Diana Sánchez-Mellado, Marta Gil-Martínez, Jessica Mireya Santillán-Coello, José Miguel Vil Biomolecules.2024; 14(1): 126. CrossRef - Biologic Therapies across Nasal Polyp Subtypes
Kody G. Bolk, Sarah K. Wise Journal of Personalized Medicine.2024; 14(4): 432. CrossRef - Evaluation of multiple-flows exhaled nitric oxide and its clinical significance in severe asthmatic patients treated with biologics: a prospective real-life study
Tommaso Pianigiani, Simona Luzzi, Akter Dilroba, Martina Meocci, Elisa Salvadori, Lorenzo Alderighi, Laura Bergantini, Miriana d’Alessandro, Piersante Sestini, Elena Bargagli, Paolo Cameli Journal of Asthma.2024; : 1. CrossRef - Long-term Safety and Efficacy of Dupilumab in Patients With Uncontrolled, Moderate-to-Severe Asthma Recruited From Korean Centers: A Subgroup Analysis of the Phase 3 LIBERTY ASTHMA TRAVERSE Trial
Chin Kook Rhee, Jung-Won Park, Heung-Woo Park, Hayeon Noh, Jerome Msihid, You Sook Cho Allergy, Asthma & Immunology Research.2024; 16(4): 372. CrossRef - Allergen Immunotherapy for the Prevention and Treatment of Asthma
Thierry Batard, Camille Taillé, Laurent Guilleminault, Andrzej Bozek, Véronique Bordas‐Le Floch, Oliver Pfaar, Walter G. Canonica, Cezmi Akdis, Mohamed H. Shamji, Laurent Mascarell Clinical & Experimental Allergy.2024;[Epub] CrossRef - Incremental net monetary benefit of biologic therapies in moderate to severe asthma: a systematic review and meta-analysis of economic evaluation studies
Sajesh K. Veettil, Vanessa Vincent, Taylor Shufelt, Emma Behan, M. Sakil Syeed, Ammarin Thakkinstian, David C. Young, Nathorn Chaiyakunapruk Journal of Asthma.2023; 60(9): 1702. CrossRef - Tackling the cytokine storm using advanced drug delivery in allergic airway disease
Vyoma K. Patel, Sukriti Vishwas, Rajan Kumar, Gabriele De Rubis, Shakti D. Shukla, Keshav Raj Paudel, Bikash Manandhar, Thakur Gurjeet Singh, Dinesh Kumar Chellappan, Monica Gulati, Indu Pal Kaur, Venkata Sita Rama Raju Allam, Philip M. Hansbro, Brian G. Journal of Drug Delivery Science and Technology.2023; 82: 104366. CrossRef - The evolving landscape of immunotherapy for the treatment of allergic conditions
Aarti Pandya, Esosa Adah, Bridgette Jones, Rachel Chevalier Clinical and Translational Science.2023; 16(8): 1294. CrossRef - Effect of Dupilumab in Korean Patients With Uncontrolled Moderate-to-Severe Asthma: A LIBERTY ASTHMA QUEST Sub-analysis
Chin Kook Rhee, Jung-Won Park, Heung-Woo Park, You Sook Cho Allergy, Asthma & Immunology Research.2022; 14(2): 182. CrossRef - The role of peripheral eosinophilia in diagnosing lung disorders: experience from a single pneumonological center
Justyna Fijołek, Elzbieta Wiatr, Dorota Piotrowska-Kownacka, Kazimierz Roszkowski-Sliz Multidisciplinary Respiratory Medicine.2021;[Epub] CrossRef - Advances in the science and treatment of respiratory diseases
Jin Hong Chung Yeungnam University Journal of Medicine.2020; 37(4): 251. CrossRef
- Microbiologic distribution and clinical features of nontuberculous mycobacteria in the tertiary hospital in Daegu.
-
Kyung Soo Hong, June Hong Ahn, Eun Young Choi, Hyun Jung Jin, Kyeong Cheol Shin, Jin Hong Chung, Kwan Ho Lee
-
Yeungnam Univ J Med. 2015;32(2):71-79. Published online December 31, 2015
-
DOI: https://doi.org/10.12701/yujm.2015.32.2.71
-
-
2,350
View
-
26
Download
-
4
Crossref
-
Abstract
PDF
- BACKGROUND
Recent studies have shown that the nontuberculosis mycobacterium (NTM) recovery rate in clinical cultures has increased within Korea. However, another study conducted by a secondary hospital within Daegu reported different results. Therefore, the purpose of this study is to understand and evaluate the microbiological distribution and clinical features of NTM in Daegu. METHODS: A retrospective study was conducted on 11,672 respiratory specimens undergoing acid fast bacilli (AFB) culture from 6,685 subjects who visited Yeungnam University Respiratory Center from January 2012 to December 2013. RESULTS: Of the 11,672 specimens undergoing AFB culture, 1,310 specimens (11.2%) showed positive results. Of these specimens, NTM was recovered from 587 specimens, showing a recovery rate of 44.8%. Identification test for NTM was performed on 191 subjects; the results were as follows: M. avium-intracellulare complex (MAC) 123 (64.4%), M. abscessus 20 (10.5%), M. kansasii 12 (6.3%), and 33 other NTM germ strains. Of the 382 subjects with NTM, 167 were diagnosed with pulmonary NTM disease (43.7%), however virulence differed depending on NTM strain. Multivariate analysis showed that nodular bronchiectasis, the nodules, and finding consistent with cavity under imaging study were statistically significant for triggering pulmonary NTM disease. AFB culture showing MAC and M. abscessus was statistically significant as well. Positive predictive value for NTM polymerase chain reaction (NTM-PCR) was 88.6%. CONCLUSION: Results for NTM recovery rate within the Daegu area were similar to those for the Seoul metropolitan area. We can assume that NTM infection is increasing in our community, therefore AFB-positive subjects (1) should undergo NTM-PCR, (2) should have their culture results checked for differentiation of mycobacterium tuberculosis complex (MTB) from NTM, and (3) undergo NTM identification test to confirm its type. Administration of treatment with the above results should be helpful in improving the patients' prognosis.
-
Citations
Citations to this article as recorded by
- Epidemiological Characteristics of Nontuberculous Mycobacterial Pulmonary Disease in South Korea: A Meta-analysis of Individual Participant Data
Geunin Lee, Sol Kim, Shihwan Chang, Hojoon Sohn, Young Ae Kang, Youngmok Park Tuberculosis and Respiratory Diseases.2024; 87(3): 386. CrossRef - Distribution and Antimicrobial Resistance of Non-Tuberculous Mycobacteria during 2015∼2020: A Single-Center Study in Incheon, South Korea
Jiwoo Kim, Hyo-Jin Ju, Jehyun Koo, Hyeyoung Lee, Hyeonhwan Park, Kyungcheol Song, Jayoung Kim The Korean Journal of Clinical Laboratory Science.2021; 53(3): 225. CrossRef - Study on the Prevalence of Lung Disease of Non-Tuberculosis Mycobacterium Isolated from Respiratory Specimens in Gwangju Second Hospital over the Last 10 Years
Hae-Gyeong Baek The Korean Journal of Clinical Laboratory Science.2020; 52(4): 349. CrossRef - Recovery Rates of Non-Tuberculous Mycobacteria from Clinical Specimens Are Increasing in Korean Tertiary-Care Hospitals
Namhee Kim, Jongyoun Yi, Chulhun L. Chang Journal of Korean Medical Science.2017; 32(8): 1263. CrossRef
|